BioSpace News Archive

Biotech Bay

Twist Bioscience’s Comprehensive DNA Synthesis Capabilities Expanded as Industry-Leading Enzymatic Synthesis Process Unveiled at Annual J.P. Morgan Healthcare Conference

Twist Bioscience Corporation today announced that it has developed an innovative, low cost, scarless and scalable enzymatic DNA synthesis process.

January 10, 2022
·
5 min read
BioMidwest

Forge Biologics Closes $80 Million in Additional Financing to Accelerate Planned CDMO Expansion

Forge Biologics announced today 2022 manufacturing expansion plans to meet the growing demand for gene therapy manufacturing.

January 10, 2022
·
4 min read
JAMP and Alvotech Announce Canadian Approval of SIMLANDI™, a High-Concentration Biosimilar to Humira®, Providing Access to Previously Unavailable Versions in Canada

Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and JAMP Pharma Group (“JAMP Pharma”), a Canadian owned pharmaceutical company headquartered in the Montreal area, announced today that Health Canada has granted marketing authorization to JAMP Pharma for a high-concentration biosimilar to Humira®.

January 10, 2022
·
13 min read
Business

Sesen Bio Further Enhances Team with Key Hires

Sesen Bio today announced the appointments of Minori Rosales, M.D., Ph.D. as Chief Development Officer as of January 24, 2022 and Stephanie Vigue as Director of Finance as of January 17, 2022.

January 10, 2022
·
8 min read
Biotech Bay

Tenaya Therapeutics Provides 2022 Business Updates

Tenaya Therapeutics, Inc. today provided a 2022 business update including the selection of TN-401 as the development candidate for the treatment of Genetic Arrhythmogenic Right Ventricular Cardiomyopathy (gARVC) due to PKP2 gene mutation.

January 10, 2022
·
7 min read
Business

Establishment Labs Announces Preliminary Fourth Quarter and Fiscal Year 2021 Revenue

Establishment Labs Inc. today reported preliminary unaudited revenue for the three months and fiscal year ended December 31, 2021.

January 10, 2022
·
6 min read
Business

Ginkgo Bioworks Adopts Inscripta’s Onyx Digital Genome Engineering Platform to Continue Accelerating its Genome Editing Throughput

Inscripta , the digital genome engineering company, today announced that Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, has adopted the Onyx™ genome engineering platform in its foundries.

January 10, 2022
·
3 min read
BioForest

Affini-T Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Affini-T Therapeutics, Inc. today announced its participation in the 40th Annual J.P. Morgan Healthcare Conference.

January 10, 2022
·
1 min read
BioForest

Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE”) Subjects

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), today announced that a research paper entitled “Leronlimab (PRO 140) activity against 4-class drug resistant HIV-1 from Heavily Treatment Experienced Subjects” has been accepted, peer reviewed and is available as a journal pre-proof on ScienceDirect.

January 10, 2022
·
12 min read
Drug Development

Veru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer

Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Phase 3 registration program for the investigation of enobosarm.

January 10, 2022
·
10 min read